Antibiotics market expands billions of pharmaceutical giants to actively prepare for the battle

The cold economy and medical reforms are on the horizon, and pharmaceutical companies are beginning to find safe havens and new opportunities.

The future environment of the pharmaceutical industry will continue to improve. The forthcoming introduction of the medical reform plan will bring about 100 billion yuan in market expansion. It will also include the new rural cooperative medical insurance policies for urban residents and the implementation of community health reforms. Both of them are for the pharmaceutical industry. It is good news.

Chen Miao, general manager of Guangzhou Baiyunshan Pharmaceutical Co., Ltd., said that Baiyun Mountain Pharmaceutical Co., Ltd. has also clearly felt the economic “cold stream”. Currently, it is taking science and technology as the guide and hopes to find “down clothing” for winter through technological innovation.

Establish the strategic position of intellectual property

On the one hand, the pharmaceutical industry is highly dependent on patents; on the other hand, developed countries have a high monopoly on patented drugs. For pharmaceutical companies, only by translating the advantages of technology and products into the advantages of intellectual property can they become the true core competitiveness of pharmaceutical companies.

Chen Mao stated that good intellectual property creation, protection, management, and use will push companies into a virtuous cycle and sustainable development. At present, Baiyunshan Pharmaceutical is committed to establishing and improving intellectual property management systems and mechanisms and accelerating the establishment of a systematic management system.

Taking cefalexin (trade name “Cinnavidin”), known as “bomb bomb”, as an example, this drug is the first and still the only new structural semi-synthetic compound that has been independently developed by Baiyunshan Pharmaceutical in China. cephalosporin. Since the product's inception, its intellectual property has been protected in all aspects of the plant. The technical advantages allow it to take full advantage of the market. According to the data, the product has only sold 1 million pieces annually since it was just listed a few years ago, and it has grown to more than 10 million pieces in sales in 2006, becoming a competitive product for Baiyun Mountain.

So far, Baiyunshan Pharmaceutical has applied for 168 patents, of which 62 are invention patents and 27 are authorized. It is reported that Baiyun Mountain has also increased its patent application in overseas markets. At present, it has applied for 2 US invention patents and 3 PCT patents.

Strengthen "Group Soldiers" Combat

It is understood that there are currently more than 6,000 pharmaceutical companies in the country, but many are small and scattered enterprises. If this medical reform is implemented, it will be an opportunity for future pharmaceutical companies to reshuffle. Chen Mao told reporters that as the competition continues to intensify, the traditional individual combat can no longer fully adapt to the development of the situation. At present, Baiyun Mountain has targeted the integration of brands and resources for antibiotics.

Chen Miao introduced that, in order to better highlight the brand's advantages, Baiyun Mountain Pharmaceutical Factory tried to collect its antibiotic species under the banner of “anti-hegemony” as the main brand, in order to distinguish it from other manufacturers' similar products. In addition, over the years, Baiyunshan Pharmaceutical has continuously invested human and financial resources to build the “Baiyun Mountain” brand building. In 2008, Beijing Famous Brand Asset Appraisal Co., Ltd. announced the latest brand assessment. The brand value of “Baiyun Mountain” was 10.52 billion yuan, which was 17% higher than in 2007. It is understood that as of now, Baiyunshan Pharmaceutical has nearly 100 registered trademarks, in addition to the "well-known trademarks", there are more than 10 trademarks were identified as Guangdong or Guangzhou famous trademarks.

Keep an eye on international drug trends

It is reported that at present, there are two new drugs in the development of Baiyunshan Pharmaceutical: one is a new type of cephalosporin, and the other is quinones products, have entered the preclinical research stage. In recent years, Baiyun Mountain has invested huge amounts of money every year to stare at the latest developments in the international pharmaceutical industry and keep pace with the market.

In addition, seize the opportunity to grab products imminent imitation of foreign patents expired, so that the factory has more international advanced level of the species is another magic weapon Baiyunshan Pharmaceutical. For example, three generations of oral cephalosporin drugs, cefprodin and cefdinir, are widely used clinically. Their patents and administrative protection expire in 2005 and 2006 respectively. The Baiyunshan Plant has already prepared for imitation as early as possible and researched and developed in advance. As soon as the patent of Cefprom Tablets expires, the Baiyunshan Plant immediately declares it to the State Drug Administration, and at the end of 2006, the product was introduced to the market. At the same time, information on new drugs in the international market, scientific research trends and market trends of the world's pharmaceutical giants are all targets of Baiyunshan Plant.